Stonehaven Incubate has partnered with human
health player Regenosine to launch Vetosine, a new company that will develop
and commercialise a first-in-class disease modifying osteoarthritis drug
(DMOAD) for animals, with an initial focus on dogs.
“Vetosine’s proprietary adenosine-based
treatment will be a real game changer for the industry,” said Charlie Dawson,
Venture Partner at Stonehaven Incubate. “At the moment, veterinarians and pet
owners have few therapy options for dogs with osteoarthritis beyond simple
nonsteroidal anti-inflammatory drugs (NSAIDs), diet and exercise. Vetosine will
provide a proven disease modifying drug that will strengthen clinical outcomes
and improve the pet’s quality of life.”
Dr. Bruce Cronstein, co-founder of Regenosine,
was first to elucidate the role of adenosine in maintaining healthy joint
cartilage.
“We have now developed proprietary formulations
for adenosine replacement which have demonstrated disease modifying outcomes in
gold standard preclinical models for osteoarthritis,” said Dr. Siddhesh Angle,
co-founder and CEO of Regenosine. “While we endeavour to make this
first-in-class therapy a success for human medicine, we are very excited to
partner with Stonehaven Incubate to expand its horizon into the animal health space.”
Vetosine will have an exclusive global license
to develop the new technology in animal health while Regenosine will continue
to focus on developing the same technology for the human health market.
“Vetosine is perfectly aligned with Stonehaven
Incubate’s mission to transform animal health by leveraging disruptive human
health technologies,” said Jarne Elleholm, CEO of Stonehaven Incubate. “We are
excited to add another company to our portfolio as we continue to explore other
opportunities to translate breakthrough human health technologies into the
animal health space.”
